Month: February 2026

AMG Reports Financial and Operating Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on February 12, 2026. Posted in Earnings Releases And Operating Results.

Company reports Diluted EPS of $11.21, Economic EPS of $9.48 in the fourth quarter of 2025Diluted EPS of $22.74, Economic EPS of $26.05 for the full year 2025Net client cash inflows of approximately $29 billion in 2025, including approximately $12 billion in the fourth quarter, driven by ongoing momentum in alternative strategies Full-year Net income (controlling interest) of $717 million, Economic net income (controlling interest) of $769 million Full-year Economic EPS of $26.05 increased 22% year-over-year, driven by strong organic growth and disciplined capital allocation Committed more than $1 billion across five new growth investments in 2025, broadening AMG’s exposure to alternative strategies Repurchased $700 million in common stock or approximately 11% of shares outstanding in 2025WEST PALM BEACH, Fla., Feb. 12, 2026 (GLOBE...

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

Written by Customer Service on February 12, 2026. Posted in Public Companies.

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflammatory responses in human immune cells using its proprietary discovery platform. Using MITOLINE™‑derived models, MitoCareX has...

Kane Biotech Restarts Commercial Activities and Strengthens North American Management

Written by Customer Service on February 12, 2026. Posted in Public Companies.

Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America. US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray Commercial Restart in the U.S. and Canada: In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, FL) and Patient Care Medical...

Fortis Inc. Files 2025 Year-End Disclosure Documents

Written by Customer Service on February 12, 2026. Posted in Public Companies.

This news release constitutes a “Designated News Release” incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis’ short form base shelf prospectus dated December 9, 2024. ST. JOHN’S, Newfoundland and Labrador, Feb. 12, 2026 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS), today filed its audited Consolidated Financial Statements, related Management Discussion and Analysis and Form 40-F for the year ended December 31, 2025, as well as its 2025 Annual Information Form, with Canadian securities regulatory authorities. The Corporation also filed its Form 40-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission. Copies of these documents are available electronically at www.sedarplus.ca (Canadian...

PyroGenesis Announces MOU Toward Joint Venture for Commercial Scale Fumed Silica Plant

Written by Customer Service on February 12, 2026. Posted in Public Companies.

PyroGenesis would build commercial fumed silica reactor for USD$20 million MONTREAL, Feb. 12, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that its client HPQ Silicon Inc. (“HPQ”), through its wholly owned subsidiary, HPQ Silica Polvere Inc. (“HSPI”), and an industrial Joint Venture partner (the “JV Partner”), have signed a non-binding memorandum of understanding (the “MOU”) to form a joint venture company (the “JV”). The purpose of the JV is to operate a 1,000 tonne per year (“1000 TPY”) fumed silica production plant. PyroGenesis, under an exclusive manufacturing arrangement, would build the fumed silica...

Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth

Written by Customer Service on February 12, 2026. Posted in Public Companies.

VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market (“ATM”) equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth. Key Highlights:ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated. Strategic institutional capital secured to fund expansion Balance sheet and liquidity significantly...

Marex Group plc to announce fourth quarter and full year 2025 results on March 3, 2026 with an Investor Day on March 26, 2026

Written by Customer Service on February 12, 2026. Posted in Public Companies.

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) — Marex Group plc (NASDAQ: MRX) today announced that it will release its fiscal 2025 fourth quarter and full year results before market open on Tuesday, March 3, 2026. The earnings release and supplementary materials will be available through the “Investors” section of the Marex website at https://ir.marex.com/. A conference call to discuss the results will take place at 9am ET the same day. If you would like to attend the live conference call you can access it here: https://events.q4inc.com/attendee/922115251 Marex will also hold an investor day on Thursday, March 26, 2026 in New York. About Marex:Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy,...

Ampersand Capital Partners Acquires Purna Pharmaceuticals

Written by Customer Service on February 12, 2026. Posted in Mergers And Acquisitions.

Purna and MedPharm to Establish Trans-Atlantic Partnership to Serve Global Clients Boston, MA, Feb. 12, 2026 (GLOBE NEWSWIRE) — Ampersand Capital Partners, a private equity firm specializing in growth investments in the life sciences and healthcare sectors, today announced its acquisition of Purna Pharmaceuticals, a trusted provider of development and manufacturing services for liquid and semi-solid dosage forms in support of pharmaceutical industry customers. “This acquisition marks an important next chapter for Purna and reflects Ampersand’s confidence in our leadership team, differentiated capabilities, and customer relationships,” said Bart Peeters, CEO Purna. “With Ampersand’s support, we are well positioned to continue investing in innovation, quality and capacity to better serve our global pharmaceutical customer base.” “Purna...

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on February 12, 2026. Posted in Earnings Releases And Operating Results.

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026 Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026 $1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 2025CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the fourth quarter and year ended December 31, 2025. “2025...

Bombardier Exceeds All 2025 Guidance Metrics, Successfully Completes its Turnaround Plan, and Sets 2026 Guidance for Strong Year Ahead

Written by Customer Service on February 12, 2026. Posted in Earnings Releases And Operating Results.

Full-year 2025 revenues surpassed guidance, growing 10% year-over-year to reach $9.55 billion. This strong performance was powered by an all-time high in Services revenues, up 13%, and 157 aircraft deliveries, an increase of 11 units year-over-year. Adjusted EBITDA(1) rose 15% year-over-year, reaching $1,559 million, with adjusted EBITDA margin(2) expanding 60 basis points to 16.3%. Reported EBIT up 26% year-over-year at $1,108 million for the full year, driving EBIT margin(3) to 11.6%, an improvement of 150 basis points. Adjusted net income(1) grew to $805 million, marking a 47% year-over-year increase, while reported net income(4) increased to $975 million, up 164%. Full-year performance translated to an adjusted EPS(2) of $7.72 and diluted EPS(4) of $9.41. Free cash flow(1) was up $840 million compared to 2024, reaching an impressive...

Month: February 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals